Pharmala Biotech Holdings (XCNQ:MDMA) Debt-to-Equity : 0.00 (As of Nov. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Pharmala Biotech Holdings Debt-to-Equity?

Pharmala Biotech Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Pharmala Biotech Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2023 was C$0.00 Mil. Pharmala Biotech Holdings's Total Stockholders Equity for the quarter that ended in Nov. 2023 was C$1.51 Mil. Pharmala Biotech Holdings's debt to equity for the quarter that ended in Nov. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Pharmala Biotech Holdings's Debt-to-Equity or its related term are showing as below:

XCNQ:MDMA' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.18 Med: 0.18 Max: 0.18
Current: 0.17

During the past 3 years, the highest Debt-to-Equity Ratio of Pharmala Biotech Holdings was 0.18. The lowest was 0.18. And the median was 0.18.

XCNQ:MDMA's Debt-to-Equity is ranked worse than
52.1% of 1069 companies
in the Biotechnology industry
Industry Median: 0.14 vs XCNQ:MDMA: 0.17

Pharmala Biotech Holdings Debt-to-Equity Historical Data

The historical data trend for Pharmala Biotech Holdings's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmala Biotech Holdings Debt-to-Equity Chart

Pharmala Biotech Holdings Annual Data

Trend

Aug21

Aug22

Aug23

Debt-to-Equity

0.18

Pharmala Biotech Holdings Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Debt-to-Equity	Get a 7-Day Free Trial						-	-	-	0.18	-

Competitive Comparison of Pharmala Biotech Holdings's Debt-to-Equity

For the Biotechnology subindustry, Pharmala Biotech Holdings's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmala Biotech Holdings's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmala Biotech Holdings's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Pharmala Biotech Holdings's Debt-to-Equity falls into.

Pharmala Biotech Holdings Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Pharmala Biotech Holdings's Debt to Equity Ratio for the fiscal year that ended in Aug. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.254	+	0)	/	1.384
	=	0.18

Pharmala Biotech Holdings's Debt to Equity Ratio for the quarter that ended in Nov. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	1.509
	=	0.00

Pharmala Biotech Holdings (XCNQ:MDMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Pharmala Biotech Holdings Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Pharmala Biotech Holdings's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmala Biotech Holdings (XCNQ:MDMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmala Biotech Holdings Inc (XCNQ:MDMA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

PMBHF:USA

Address

82 Richmond Street East, Toranto, ON, CAN, M5C 1P1

Website

https://www.pharmala.ca

Pharmala Biotech Holdings Inc is focused on manufacturing and sales of MDMA and MDXX Active Pharmaceutical Ingredients (API) for use in clinical research. PharmAla's drug API is manufactured and encapsulated under GMP conditions. The Company generates revenue from the sale of tablets and raw MDMA and MDXX compounds/formulations.

Pharmala Biotech Holdings (XCNQ:MDMA) Headlines

No Headlines